NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









A-Alpha Bio

A-Alpha Bio

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.aalphabio.com/

Last Round

Grant

May 21, 2024

Total Funding Raised

$65.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

A-Alpha Bio is a biotechnology company that combines synthetic biology and machine learning to analyze protein-protein interactions for drug discovery and development.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Revenue Share

AI Layer

Infrastructure

Keywords

drug discoveryprotein interactionsynthetic biologyprotein therapeuticsbispecific antibodiesmachine learningin silico drug discoveryhigh-throughput screeningprotein engineeringbinding affinityai drug discoverybiotech platformcomputational biologyppide novo design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

A-Alpha Bio Comparables

Compare A-Alpha Bio with similar companies based on industry and business-model similarity.

A-Alpha Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DeepSeq.AI, Inc.
82%
Aikium
81%
BigHat Biosciences
81%

A-Alpha Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 21, 2024
Series A ExtensionJul 25, 2023
GrantMay 17, 2023
GrantMar 1, 2022
Series ASep 8, 2021
Grant
Sep 1, 2020

Key People

Founding team and executive leadership

Randolph Lopez

Co-founder CTO

Founding Team

David Younger

Co-Founder And CEO

Founding Team

A-Alpha Bio Investors

Notable investors and investment history

A-Alpha Bio investors
InvestorRounds
Perceptive AdvisorsSeries A, Series A Extension
United States Department of DefenseGrant
XontogenySeries A
Boom CapitalSeed
Lux CapitalSeries A
Social CapitalGrant
Breakout VenturesSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 3, 2026

    Partnered with Novo Nordisk to enhance drug discovery using its AI platform.

  • Sep 23, 2025

    Troy Lionberger appointed to drive next phase of growth.

A-Alpha Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

A-Alpha Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about A-Alpha Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range50
Year Founded2017
Last FundingMay 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.